COR · 8-K · 20260805PR000032
Acquisition / Partnership / Divestiture
Cencora, Inc. · 2026-08-05 · Importance 65 · Surprise 60 · In source text
Cencora’s February 2026 acquisition of OneOncology materially affected its operating structure and financial outlook. The company reported $4.97 billion of cash spent on acquired companies during the nine months ended June 30, 2026, and recorded a $1.1 billion gain from remeasuring its existing OneOncology equity-method investment and extinguishing the related put-option liability. The acquisition was partly financed through $3.0 billion of senior notes and $1.5 billion of variable-rate term loans. Cencora also divested its U.S. Consulting Services business in April 2026 and classified related assets and liabilities as held for sale.
Key facts
- In the nine months ended June 30, 2026, cost of acquired companies, net of cash acquired: $(4,973,696) thousand (OneOncology acquisition financing referenced) source
- Cencora acquired OneOncology in February 2026 (referenced as February 2026 acquisition of OneOncology) and attributes certain gross profit and expense impacts to that acquisition source
- Acquisition-related intangibles amortization depends on the timing and amount of future acquisitions source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | -5.9% | In the nine months ended June 30, 2026, cost of acquired companies, net of cash acquired: $(4,973,696) thousand (OneOncology acquisition… |
| operating_income | mixed | realized | — | Cencora acquired OneOncology in February 2026 (referenced as February 2026 acquisition of OneOncology) and attributes certain gross profit… |